Telo Genomics Corp.

TELO

CA87975M2085

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 17:12:32 28/06/2024 BST			5-day change	1st Jan Change
0.185 ^CAD	-9.76%		0.00%	-7.50%

06-21	Telo Genomics Corp. announced that it has received CAD 0.65 million in funding	CI
06-18	Telo Genomics' Myeloma Test Accepted as Lab Developed Test by College of American Pathologists	MT

3D Signatures Inc. Announces Resignation of Bruce Colwill as Director

October 10, 2017 at 12:50 pm

3D Signatures Inc. announced that Bruce Colwill has resigned as a director of the company effective immediately.

Latest news about Telo Genomics Corp.

Telo Genomics Corp. announced that it has received CAD 0.65 million in funding	06-20	CI
Telo Genomics' Myeloma Test Accepted as Lab Developed Test by College of American Pathologists	06-18	MT
Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic Tests	06-12	CI
Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in funding	06-03	CI
Telo Genomics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-28	CI
Telo Genomics Corp. Signs Collaboration Agreement with Emery Pharma	05-15	CI
Telo Genomics Receives Accreditation from College of American Pathologists	04-10	MT
Telo Genomics Corp. Receives Accreditation from College of American Pathologists	04-10	CI
Telo Genomics' MRD Clinical Trial Expands into Multi-Center Trial; Shares up 9.5%	04-02	MT
Telo Genomics Corp. Announces Patient Recruitment for Its Minimal Respiratory Disease Clinical Trial Has Been Initiated, with Several Patient Samples Received and Processed to Date	04-02	CI
Telo Genomics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-27	CI
Telo Genomics Corp. Initiates MRD Clinical Trial for Multiple Myeloma Patients	02-13	CI
Telo Genomics Corp. Announces Executive Changes	12-08	CI
Telo Genomics Corp. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-22	CI
Telo Genomics Corp. Announces the American Society of Hematology Accepts the Results of Teloview-Smm Technical Repeatability Validation for Presentation At Their Annual Meeting in December 10, 2023	11-01	CI
Telo Genomics Corp. Reports Earnings Results for the Full Year Ended June 30, 2023	30/10/23	CI
Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone Achieved	17/10/23	CI
Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting	12/10/23	CI
Telo Genomics Corp. Reports Substantial Progress Toward Clinical Launch of Teloview-SMM	28/08/23	CI
Telo Genomics Closes $2.8 Million Financing	14/06/23	MT
Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding	13/06/23	CI
Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023	12/06/23	CI
Telo Genomics Corp. Presents Superior Results of Its Smoldering Multiple Myeloma Studies At Asco 2023	05/06/23	CI
Telo Genomics Seeks to Raise $2 Million via Non-Brokered Private Placement	19/05/23	MT
Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding	18/05/23	CI

Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.

Sector

Biotechnology & Medical Research

Calendar

28/10/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
TELO GENOMICS CORP.	-7.50%	9.64M
EXACT SCIENCES CORPORATION	-42.89%	7.8B
GUARDANT HEALTH, INC.	+6.77%	3.53B
IOVANCE BIOTHERAPEUTICS, INC.	-1.35%	2.24B
BGI GENOMICS CO., LTD.	-27.06%	1.84B
VERACYTE, INC.	-21.23%	1.66B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+9.31%	951M
CAREDX, INC	+29.42%	811M
SEEGENE, INC.	-12.66%	670M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-26.12%	533M